A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma

David Kayembe Mwimbi; Zhang Gaochenxi; Wenpei Zhu; Ying Wang; Liang Yi; Wang Dan; Chen Huihui; Shu Qijin

doi:doi:10.11648/j.ijcocr.20200503.11

| Peer-Reviewed

A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma

David Kayembe Mwimbi, Zhang Gaochenxi, Wenpei Zhu, Ying Wang, Liang Yi, Wang Dan, Chen Huihui, Shu Qijin

Published in International Journal of Clinical Oncology and Cancer Research (Volume 5, Issue 3)

Received: 27 February 2020 Accepted: 12 March 2020 Published: 23 July 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective: Several systematic reviews for Therapeutic Effect of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma have recently emerged evidence. However, limited data are available regarding the activity of available EGFR TKIs against uncommon EGFR mutations. This meta-analysis evaluates the efficacy of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma. So therefore, Lung Adenocarcinoma related diseases have a profound economic impact on health care systems global wide, thus Kanglaite Injection combined with First-Line EGFR –TKIs have been shown to have beneficial effects than treatment with First-Line EGFR Tyrosine Kinase Inhibitors (TKIs) Alone. Methods: We electronically searched the literature of the China National Knowledge Infrastructure (Chinese language, English 2010-2019), Pub Med, Cochrane Central Register of Controlled Trails from database inception, CNKI, web of science Wang Fang, and manually searched Chinese-language oncology journals to identify randomized controlled trials (RCTs) of Kanglaite Injection Plus First Line EGFR-TKIs Versus First Line EGFR- TKIs Alone, regardless of their having been published or not, blinding, duration of treatment, or duration of follow-up. The quality of the included trials was assessed using the method recommended by The Cochrane Collaboration (CC). If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model was used. Results: Electronic database searches yielded 1780 citations with NSCLC. Articles or Records Excluded by screening of the title/abstract level total 510, Records which are not Rcts 430, Study with no EGFR mutation analysis 590, Due to duplicated publication 180. Finally, we identified full text articles retrieved for detailled evaluation 70. The sample size of each trial had calculated by Rev Man 5.3. Pooled analyses performed using both fixed- and random-effects models revealed that compared with First Line of Egfr-Tkis alone, KLT injection plus First Line of Egfr-Tkis improved the response rate (relative risk [RR}, 1.34; 95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.2 0-1.51, respectively). KLT injection plus First Line of Egfr-Tkis was associated with improvement in the symptoms of cough, dyspnea, chest pain, fatigue, and anorexia.

Published in	International Journal of Clinical Oncology and Cancer Research (Volume 5, Issue 3)
DOI	10.11648/j.ijcocr.20200503.11
Page(s)	43-55
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

Meta-Analysis, Kanglaite Injection, Egfr-Tkis, Stage IIIB A Lung Adenocarcinoma

References

[1]	Molina JR, Ad jei AA, JettJR. Advances in chemotherapy ofnon-small cell lung cancer. Chest. 2006; 130: 1211-1219.
[2]	The American Cancer Society medical and editorial content team.www.cancer.org.
[3]	Encun H, Jie C, Lu G, Hang S, Jing D. Systematic evaluation of the efficacy of Kanglaite combined with GP regimenting the treatment of advanced non-small cell lung cancer [J]. Mod On col Med 2015; 7: 960-965.
[4]	Yuan W, Shuang H, Min L, Qi F, Zhao L. Clinical study of Kanglaite injection in the treatment of advanced non-small cell lung cancer with gemcitabine combined with cisplatin regimen [J]. Chin J Clin Pharm 2017; 33: 2354-2356, 2360.
[5]	Bao Y., Xia L., Jang H. The experiment and study on cellular apoptosis produced by KLT Injections in pancreatic cancer cells. Shanghai Journal Medicine. 2004; 27: 421–424. [Google Scholar].
[6]	Schwartzberg L. S., Arena F. P., Bienvenu B. J., et al. A randomized, open-label, safety and exploratory efficacy study of Kanglaite injection (KLTi) plus gemcitabine versus gemcitabine in patients with advanced pancreatic cancer. Journal of Cancer. 2017; 8 (10): 1872–1883. Doi: 10.7150/jca.15407. [PMC free article] [PubMed] [CrossRef] [Google Scholar].
[7]	Shi G., Zheng X., Zhang S., et al. Kanglaite inhibits EMT caused by TNF-α via NF-κΒ inhibition in colorectal cancer cells. Oncotarget. 2017; 9: 6771–6779. Doi: 10.18632/oncotarget.23645. [PMC free article] [PubMed] [CrossRef] [Google Scholar].
[8]	Xinna D, Shufang Z, Yang L, Wei MQ, Zhou SF. Therapeutic effect of Kanglaite injection combined with chemotherapy on elderly patients with advanced non-small cell lung cancer [J]. Mod J Integr Tradit Chin West Med 2015; 18: 1951-1953, 1957.
[9]	Hongxue Z, Chunsheng Z, Lianbin L, Galluzzi L, Senovilla L. Effects of Kanglaite combined with gefitinib on immune function and quality of life in patients with advanced non-small cell lung cancer [J]. Chin J Pract Diagn Ther 2014; 28: 930-931.
[10]	Ting J, Qi P. Evaluation of efficacy and safety of Kanglaite combined with chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: Meta-analysis [J]. Int J Res 2017; 37: 116-123.
[11]	Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann Intern Med. 2014; 160: 517-525.
[12]	Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 13 Regs Research Data with Delay-Adjustment, Malignant Only, Nov. 2017 Sub (1992–2015) xxaaa Katrina/Rita Population Adjustmentxxbbb-Linked To County Attributes-Total US, 1969–2016 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2017.
[13]	Jun Y, Xiao S. Clinical analysis of gemcitabine and cisplatin combined with Kanglaite injection in the treatment of advanced non-small cell lung cancer [J]. J Clin Exp Med 2017; 16: 1195-1198.
[14]	Yinzhong Q. The effect of Kanglaite combined with radiotherapy on non-small cell lung cancer and immune function of patients [J]. Pract J Cancer 2016; 31: 578-580.
[15]	Meng H, Shubo C, Qing S, Xu J. Efficacy and safety of GP regimen combined with Kanglaite injection in the treatment of advanced non-small cell lung cancer [J]. Pract J Cancer 2017; 32: 289-291.
[16]	Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.

Cite This Article

Plain Text BibTeX RIS

APA Style

David Kayembe Mwimbi, Zhang Gaochenxi, Wenpei Zhu, Ying Wang, Liang Yi, et al. (2020). A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma. International Journal of Clinical Oncology and Cancer Research, 5(3), 43-55. https://doi.org/10.11648/j.ijcocr.20200503.11

Copy | Download

ACS Style

David Kayembe Mwimbi; Zhang Gaochenxi; Wenpei Zhu; Ying Wang; Liang Yi, et al. A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma. Int. J. Clin. Oncol. Cancer Res. 2020, 5(3), 43-55. doi: 10.11648/j.ijcocr.20200503.11

Copy | Download

AMA Style

David Kayembe Mwimbi, Zhang Gaochenxi, Wenpei Zhu, Ying Wang, Liang Yi, et al. A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma. Int J Clin Oncol Cancer Res. 2020;5(3):43-55. doi: 10.11648/j.ijcocr.20200503.11

Copy | Download

@article{10.11648/j.ijcocr.20200503.11,
  author = {David Kayembe Mwimbi and Zhang Gaochenxi and Wenpei Zhu and Ying Wang and Liang Yi and Wang Dan and Chen Huihui and Shu Qijin},
  title = {A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {5},
  number = {3},
  pages = {43-55},
  doi = {10.11648/j.ijcocr.20200503.11},
  url = {https://doi.org/10.11648/j.ijcocr.20200503.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20200503.11},
  abstract = {Objective: Several systematic reviews for Therapeutic Effect of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma have recently emerged evidence. However, limited data are available regarding the activity of available EGFR TKIs against uncommon EGFR mutations. This meta-analysis evaluates the efficacy of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma. So therefore, Lung Adenocarcinoma related diseases have a profound economic impact on health care systems global wide, thus Kanglaite Injection combined with First-Line EGFR –TKIs have been shown to have beneficial effects than treatment with First-Line EGFR Tyrosine Kinase Inhibitors (TKIs) Alone. Methods: We electronically searched the literature of the China National Knowledge Infrastructure (Chinese language, English 2010-2019), Pub Med, Cochrane Central Register of Controlled Trails from database inception, CNKI, web of science Wang Fang, and manually searched Chinese-language oncology journals to identify randomized controlled trials (RCTs) of Kanglaite Injection Plus First Line EGFR-TKIs Versus First Line EGFR- TKIs Alone, regardless of their having been published or not, blinding, duration of treatment, or duration of follow-up. The quality of the included trials was assessed using the method recommended by The Cochrane Collaboration (CC). If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model was used. Results: Electronic database searches yielded 1780 citations with NSCLC. Articles or Records Excluded by screening of the title/abstract level total 510, Records which are not Rcts 430, Study with no EGFR mutation analysis 590, Due to duplicated publication 180. Finally, we identified full text articles retrieved for detailled evaluation 70. The sample size of each trial had calculated by Rev Man 5.3. Pooled analyses performed using both fixed- and random-effects models revealed that compared with First Line of Egfr-Tkis alone, KLT injection plus First Line of Egfr-Tkis improved the response rate (relative risk [RR}, 1.34; 95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.2 0-1.51, respectively). KLT injection plus First Line of Egfr-Tkis was associated with improvement in the symptoms of cough, dyspnea, chest pain, fatigue, and anorexia.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma
AU  - David Kayembe Mwimbi
AU  - Zhang Gaochenxi
AU  - Wenpei Zhu
AU  - Ying Wang
AU  - Liang Yi
AU  - Wang Dan
AU  - Chen Huihui
AU  - Shu Qijin
Y1  - 2020/07/23
PY  - 2020
N1  - https://doi.org/10.11648/j.ijcocr.20200503.11
DO  - 10.11648/j.ijcocr.20200503.11
T2  - International Journal of Clinical Oncology and Cancer Research
JF  - International Journal of Clinical Oncology and Cancer Research
JO  - International Journal of Clinical Oncology and Cancer Research
SP  - 43
EP  - 55
PB  - Science Publishing Group
SN  - 2578-9511
UR  - https://doi.org/10.11648/j.ijcocr.20200503.11
AB  - Objective: Several systematic reviews for Therapeutic Effect of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma have recently emerged evidence. However, limited data are available regarding the activity of available EGFR TKIs against uncommon EGFR mutations. This meta-analysis evaluates the efficacy of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma. So therefore, Lung Adenocarcinoma related diseases have a profound economic impact on health care systems global wide, thus Kanglaite Injection combined with First-Line EGFR –TKIs have been shown to have beneficial effects than treatment with First-Line EGFR Tyrosine Kinase Inhibitors (TKIs) Alone. Methods: We electronically searched the literature of the China National Knowledge Infrastructure (Chinese language, English 2010-2019), Pub Med, Cochrane Central Register of Controlled Trails from database inception, CNKI, web of science Wang Fang, and manually searched Chinese-language oncology journals to identify randomized controlled trials (RCTs) of Kanglaite Injection Plus First Line EGFR-TKIs Versus First Line EGFR- TKIs Alone, regardless of their having been published or not, blinding, duration of treatment, or duration of follow-up. The quality of the included trials was assessed using the method recommended by The Cochrane Collaboration (CC). If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model was used. Results: Electronic database searches yielded 1780 citations with NSCLC. Articles or Records Excluded by screening of the title/abstract level total 510, Records which are not Rcts 430, Study with no EGFR mutation analysis 590, Due to duplicated publication 180. Finally, we identified full text articles retrieved for detailled evaluation 70. The sample size of each trial had calculated by Rev Man 5.3. Pooled analyses performed using both fixed- and random-effects models revealed that compared with First Line of Egfr-Tkis alone, KLT injection plus First Line of Egfr-Tkis improved the response rate (relative risk [RR}, 1.34; 95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.2 0-1.51, respectively). KLT injection plus First Line of Egfr-Tkis was associated with improvement in the symptoms of cough, dyspnea, chest pain, fatigue, and anorexia.
VL  - 5
IS  - 3
ER  -

Copy | Download

Author Information

David Kayembe Mwimbi

The First Clinical Medical College of Medicine, Zhejiang Chinese Medical University (International Education College IEC), Hangzhou, P. R. China
Zhang Gaochenxi

The First Clinical Medical College of Medicine, Zhejiang Chinese Medical University (International Education College IEC), Hangzhou, P. R. China
Wenpei Zhu

The First Clinical Medical College of Medicine, Zhejiang Chinese Medical University (International Education College IEC), Hangzhou, P. R. China
Ying Wang

The First Clinical Medical College of Medicine, Zhejiang Chinese Medical University (International Education College IEC), Hangzhou, P. R. China
Liang Yi

The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, P. R. China
Wang Dan

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, P. R. China
Chen Huihui

Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, P. R. China
Shu Qijin

Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, P. R. China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

David Kayembe Mwimbi, Zhang Gaochenxi, Wenpei Zhu, Ying Wang, Liang Yi, et al. (2020). A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma. International Journal of Clinical Oncology and Cancer Research, 5(3), 43-55. https://doi.org/10.11648/j.ijcocr.20200503.11

Copy | Download

ACS Style

David Kayembe Mwimbi; Zhang Gaochenxi; Wenpei Zhu; Ying Wang; Liang Yi, et al. A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma. Int. J. Clin. Oncol. Cancer Res. 2020, 5(3), 43-55. doi: 10.11648/j.ijcocr.20200503.11

Copy | Download

AMA Style

David Kayembe Mwimbi, Zhang Gaochenxi, Wenpei Zhu, Ying Wang, Liang Yi, et al. A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma. Int J Clin Oncol Cancer Res. 2020;5(3):43-55. doi: 10.11648/j.ijcocr.20200503.11

Copy | Download

@article{10.11648/j.ijcocr.20200503.11,
  author = {David Kayembe Mwimbi and Zhang Gaochenxi and Wenpei Zhu and Ying Wang and Liang Yi and Wang Dan and Chen Huihui and Shu Qijin},
  title = {A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma},
  journal = {International Journal of Clinical Oncology and Cancer Research},
  volume = {5},
  number = {3},
  pages = {43-55},
  doi = {10.11648/j.ijcocr.20200503.11},
  url = {https://doi.org/10.11648/j.ijcocr.20200503.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20200503.11},
  abstract = {Objective: Several systematic reviews for Therapeutic Effect of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma have recently emerged evidence. However, limited data are available regarding the activity of available EGFR TKIs against uncommon EGFR mutations. This meta-analysis evaluates the efficacy of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma. So therefore, Lung Adenocarcinoma related diseases have a profound economic impact on health care systems global wide, thus Kanglaite Injection combined with First-Line EGFR –TKIs have been shown to have beneficial effects than treatment with First-Line EGFR Tyrosine Kinase Inhibitors (TKIs) Alone. Methods: We electronically searched the literature of the China National Knowledge Infrastructure (Chinese language, English 2010-2019), Pub Med, Cochrane Central Register of Controlled Trails from database inception, CNKI, web of science Wang Fang, and manually searched Chinese-language oncology journals to identify randomized controlled trials (RCTs) of Kanglaite Injection Plus First Line EGFR-TKIs Versus First Line EGFR- TKIs Alone, regardless of their having been published or not, blinding, duration of treatment, or duration of follow-up. The quality of the included trials was assessed using the method recommended by The Cochrane Collaboration (CC). If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model was used. Results: Electronic database searches yielded 1780 citations with NSCLC. Articles or Records Excluded by screening of the title/abstract level total 510, Records which are not Rcts 430, Study with no EGFR mutation analysis 590, Due to duplicated publication 180. Finally, we identified full text articles retrieved for detailled evaluation 70. The sample size of each trial had calculated by Rev Man 5.3. Pooled analyses performed using both fixed- and random-effects models revealed that compared with First Line of Egfr-Tkis alone, KLT injection plus First Line of Egfr-Tkis improved the response rate (relative risk [RR}, 1.34; 95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.2 0-1.51, respectively). KLT injection plus First Line of Egfr-Tkis was associated with improvement in the symptoms of cough, dyspnea, chest pain, fatigue, and anorexia.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - A Meta-Analysis of the Effectiveness of Kanglaite Injection Plus First-Line EGFRTKIs Versus First-Line EGFRTKIs Alone Stage IIIB Lung Adenocarcinoma
AU  - David Kayembe Mwimbi
AU  - Zhang Gaochenxi
AU  - Wenpei Zhu
AU  - Ying Wang
AU  - Liang Yi
AU  - Wang Dan
AU  - Chen Huihui
AU  - Shu Qijin
Y1  - 2020/07/23
PY  - 2020
N1  - https://doi.org/10.11648/j.ijcocr.20200503.11
DO  - 10.11648/j.ijcocr.20200503.11
T2  - International Journal of Clinical Oncology and Cancer Research
JF  - International Journal of Clinical Oncology and Cancer Research
JO  - International Journal of Clinical Oncology and Cancer Research
SP  - 43
EP  - 55
PB  - Science Publishing Group
SN  - 2578-9511
UR  - https://doi.org/10.11648/j.ijcocr.20200503.11
AB  - Objective: Several systematic reviews for Therapeutic Effect of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma have recently emerged evidence. However, limited data are available regarding the activity of available EGFR TKIs against uncommon EGFR mutations. This meta-analysis evaluates the efficacy of Kanglaite Injection Plus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Versus First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Alone In Stage IIIB Advanced Lung Adenocarcinoma. So therefore, Lung Adenocarcinoma related diseases have a profound economic impact on health care systems global wide, thus Kanglaite Injection combined with First-Line EGFR –TKIs have been shown to have beneficial effects than treatment with First-Line EGFR Tyrosine Kinase Inhibitors (TKIs) Alone. Methods: We electronically searched the literature of the China National Knowledge Infrastructure (Chinese language, English 2010-2019), Pub Med, Cochrane Central Register of Controlled Trails from database inception, CNKI, web of science Wang Fang, and manually searched Chinese-language oncology journals to identify randomized controlled trials (RCTs) of Kanglaite Injection Plus First Line EGFR-TKIs Versus First Line EGFR- TKIs Alone, regardless of their having been published or not, blinding, duration of treatment, or duration of follow-up. The quality of the included trials was assessed using the method recommended by The Cochrane Collaboration (CC). If heterogeneity existed among subgroups, then overall results (OS) were calculated based on a random-effects model; otherwise, a fixed effects model was used. Results: Electronic database searches yielded 1780 citations with NSCLC. Articles or Records Excluded by screening of the title/abstract level total 510, Records which are not Rcts 430, Study with no EGFR mutation analysis 590, Due to duplicated publication 180. Finally, we identified full text articles retrieved for detailled evaluation 70. The sample size of each trial had calculated by Rev Man 5.3. Pooled analyses performed using both fixed- and random-effects models revealed that compared with First Line of Egfr-Tkis alone, KLT injection plus First Line of Egfr-Tkis improved the response rate (relative risk [RR}, 1.34; 95% CI, 1.19-1.51 and RR, 1.35; 95% CI, 1.2 0-1.51, respectively). KLT injection plus First Line of Egfr-Tkis was associated with improvement in the symptoms of cough, dyspnea, chest pain, fatigue, and anorexia.
VL  - 5
IS  - 3
ER  -

Copy | Download